News >

Trastuzumab Regimen Extends PFS in Rare Endometrial Cancer

Jason Harris
Published: Friday, Mar 30, 2018

Alessandro D. Santin, MD
Alessandro D. Santin, MD
Adding trastuzumab (Herceptin) to chemotherapy increased progression-free survival (PFS) for patients with advanced HER2/neu-positive uterine serous carcinoma, including those with recurrent disease and patients undergoing primary treatment.

= .01).
Fader AN, Roque DM, Siegel E, et al. Randomized phase ii trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2/neu [published online March 27, 2018]. J Clin Oncol. doi: 10.1200/JCO.2017.76.5966.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication